Leading Australian pharmaceutical firm Phebra is pleased to announce the appointment of highly-experienced pharmaceutical marketing executive Sarah Elliott to the newly-created role of Chief Marketing and Sales Officer, Australia-New Zealand (ANZ)
With a career spanning over 25 years, Ms Elliott has a breadth of experience in the pharmaceutical industry, working in leadership roles at CSL, Mayne Pharma and Roche, where she developed and led high-performance sales and marketing teams from pre-launch to portfolio life cycle management in both GP and specialty markets.
Commenting on her appointment, Ms Elliott said: "I am incredibly excited to be joining Phebra, a truly innovative Australian pharmaceutical company with domestic development and manufacturing capability strategies to grow its portfolio.
"At the core of everything Phebra does is helping Australian patients with critical medicines. Whether it be producing a generic to help with market supply issues, in-licensing a specialty product that otherwise wouldn't be available here, or developing a solution with a healthcare professional to address an unmet need, the whole business genuinely works to achieve better outcomes for Australian patients, so that is extremely motivating for me."
The newly-created function of Phebra Chief Marketing & Sales Officer combines the previous roles of Chief Marketing Officer, Hari Papapetrou and Chief Regional Commercial Officer – Apac, Gios Auteri. Mr. Auteri is retiring after a distinguished 15 year career at Phebra, whilst Ms Papapetrou will move into the newly established position of Chief Global Product Officer, as part of our executive restructuring initiative.
Phebra CEO Andre Vlok explained: "As a dynamic, highly-regarded pharmaceutical marketing executive with a proven track record of product launches, brand management and growth in multiple therapeutic areas, Sarah is the ideal appointment for this key, new role to lead Phebra's ANZ commercialisation team."
Mr. Vlok added: "As part of our new operating model, I'm delighted that Hari will be taking up the position of Chief Global Product Officer, with the aim of driving the growth and extent of Phebra's domestic and global portfolio across a range of therapeutic areas.
"I would also like to thank Gios for his dedication and commitment to Phebra. His professionalism, drive and energy in building the business over the last 15 years has placed Phebra in a strong commercial position for the future and we wish him well on his retirement."
About us:
About Phebra
Phebra is an Australian based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia and across the world.
